Cipla InvaGen US facility classified VAI by USFDA after inspection

Regulatory & Legal View source PDF Explain this filing

CIPLA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.4%Reaction day

₹1415.00

prior close

₹1418.00

announcement price

After-mkt

timing

Nifty 100market-0.4%+0.0% vs market

Pharmaceuticals peers, median of 174sector-0.3%-0.1% vs sector

On the reaction day the stock moved in line with Nifty 100 and 0.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

-0.1

15m

+0.0

30m

-0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.4-0.4+0.0-0.3-0.1

Next day

+0.1-0.7+0.9-0.7+0.8

-0.4-1.2+0.8-0.5+0.1

-1.8-1.3-0.5-0.2-1.6

-2.1-1.3-0.9-0.0-2.1

-1.4-1.7+0.3+0.0-1.4

-3.7-2.8-0.8+0.1-3.8

15d

-2.6-3.4+0.9+0.2-2.8

-4.9-6.3+1.5+0.0-4.9

—————

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 174Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

USFDA inspected Cipla's wholly owned subsidiary InvaGen Pharmaceuticals Unit 3 facility in Central Islip, Long Island, New York from 13 July to 17 July 2026. On 28 August 2026, USFDA classified the inspection outcome as Voluntary Action Indicated (VAI). This means no mandatory regulatory action is required, though the facility may voluntarily address any observations noted. VAI is a relatively favourable classification compared to Official Action Indicated.

Likely market impact

Positive outcome. VAI classification avoids USFDA enforcement action on InvaGen Unit 3, though minor voluntary corrections may be needed.